Doses - PHENYLPROPANOLAMINE HCL

Dogs:

For urethral sphincter hypotonus:
a) 12.5 - 50 mg PO q8h (Labato 1988), (Polzin and Osborne 1985)
b) 1.1 mg/kg PO q8h; dosage should be rounded to the nearest 12.5 mg for practicaldosing. (Plumb 1988)

Cats:

For urethral sphincter hypotonus:
a) 12.5 mg PO q8h (Labato 1988), (Polzin and Osborne 1985)
b) One 75 mg sustained-release capsule once daily PO (Cornell 1985)
Monitoring Parameters -

1) Clinical effectiveness

2) Adverse effects (see above)

3) Blood pressure, if possible
Client Information - For this drug to be effective, it must be administered as directed by theveterinarian; missed doses will negate its effect. It may take several days for the full benefit of thedrug to take place. Contact veterinarian if the animal demonstrates ongoing changes in behavior(restlessness, irritability) or if incontinence persists or increases.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None
Human-Approved Products: Note: Phenylpropanolamine is available in combination with manyother agents, including antihistamines, analgesics, decongestants, antitussives and expectorants.
Sustained release capsules and tablets are also available. Most veterinary use has been with the non-sustained release oral tablets. A listing of these products follow:
Phenylpropanolamine 25 mg, 50 mg Tablets; Propagest® (Reed & Carnick); generic, (OTC)
Phenylpropanolamine Capsules, Timed Release 75 mg; Various (OTC)